CA-KAVA-LABS
31.8.2021 14:49:07 CEST | Business Wire | Press release
Kava Labs™, an open source and non-custodial developer of financial products and services for decentralized finance (DeFi), announced the successful launch of its newest platform project, Kava Swap™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005132/en/
Kava Swap is a cross-chain Autonomous Market Making (AMM) protocol designed to provide an efficient and safe way to swap natively between the world’s largest assets. The new protocol is built on the Kava Platform™ and is backed by low fees, high efficiency, and the ability to generate strong returns for liquidity providers. Kava Swap gives both retail and institutional users access to the over $1 billion of on-chain liquidity on the Kava ecosystem to efficiently trade assets, extend earning opportunities and maximize yields. The new product comes as part of the Kava Mainnet 8 upgrade and has successfully completed a full security audit with CertiK.
“From our inception four years ago, Kava Labs’ mission has been to build a portfolio of decentralized products and services that allow users to gain access to all of the benefits of DeFi, but without the risks present in the current marketplace,” said Scott Stuart, Co-Founder and Head of Products at Kava Labs. “As we expand our ecosystem, Kava continues to deliver on the promise of constructing an open and scalable institutional-grade platform that provides the same level of efficiency, security and ease of use as main street financial products.”
Kava Swap is the third protocol built on the Kava Platform and is an open and permissionless application accessible by anyone, anytime, anywhere in the world. It joins Kava Mint™, which allows users to take out USDX stablecoin loans using their assets as collateral, and Kava Lend™, which allows users to earn rewards by supplying and borrowing assets from money markets. All three protocols come complete with interoperable cross-chain tooling, secure price feeds and institutional-grade safety and reliability. In addition, the Platform’s upgrade to Kava Mainnet 8 will strengthen token holder participation and governance across all applications on the Kava Platform by activating voting on the HARD™ and SWP™ tokens. This gives token investors direct access to governance over the Kava Platform and the Mint Protocol through the KAVA™ token, the Kava Lend Protocol through the HARD token and the Kava Swap Protocol with the SWP token.
“Kava has been focused on developing the safest way for users to grow their cryptocurrency portfolios,” continued Stuart. “We believe that accessing the wealth creating opportunities inside of DeFi does not need to mean increased exposure to risks. Our guiding product principle is to develop an institutional-grade DeFi ecosystem that unlocks the massive growth opportunities available in the crypto marketplace in a de-risked model that helps to evolve our marketplace into the mainstream.”
For more information please visit https://www.kava.io
To Access Kava Swap, please visit: https://app.kava.io
Follow on Twitter:
https://twitter.com/kava_labs
Follow on Telegram: https://
http://t.me/kavalabs
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom